



Press Release

1 April 2009

Management information from Tripep

As previously announced The Board of Tripep's has come to a mutual understanding with Tripep's CEO Jan Nilsson that he will leave the Company. During a transitional stage Anders Vahlne, Head of Research and Development, will be the acting CEO after Jan Nilsson. Anders Vahlne will take office on 1 April 2009.

For more information, please contact:

Anders Vahlne, CEO & Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se

About Tripep

Tripep develops drugs against chronic disease based on proprietary and other parties' patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal[®] and a therapeutic vaccine against Hepatitis C, named ChronVac-C[®], plus the RAS[®] technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company's website: www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.